PHARMAC is seeking feedback on a proposal involving the funding of haemophilia treatments. The treatments include recombinant factor VIII (rFVIII), recombinant factor IX (rFIX), recombinant factor VIIa (rFVIIa) and factor VIII inhibitor bypassing fraction. We have reached provisional agreements for the listing and supply of these treatments.

PHARMAC is seeking feedback on its proposal, with a closing date for submissions of Monday, 15 June 2015.

For more details, go to: http://www.pharmac.health.nz/news/consultation-2015-05-26-haemophilia/